Pulmonx Corporation — Cyborg Score 4/10

Mixed
Medical Devices - Respiratory/Pulmonary Care

Strategic Profile

Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients. In Q2 2025, the company achieved total revenue of $23.9 million, representing a 15% year-over-year increase, driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).

Cyborg Score Rationale

Pulmonx stock trades at $3.77 per share with a market capitalization of $150.03M, representing a -90.41% return since its October 2020 IPO listing at $39.31. The company maintains a strong gross margin of 72% but reported a net loss of $15.2 million in Q2 2025. While revenue growth is solid with 15% YoY increase, the company faces significant profitability challenges.

Top Insights

  • Q2 2025 revenue of $23.9M showed 15% YoY growth with international markets expanding faster (32%) than domestic U.S. market (6%)
  • Company maintains healthy 72% gross margin despite significant net losses, indicating product economics are sound but scale is insufficient
  • Strong cash position of $101.74M can cover annual cash burn of $32.98M for over three years, providing runway for growth initiatives
  • Recent executive hires including new CFO in Q4 2025 suggest potential strategic pivots or operational restructuring to address profitability

Named Competitors

  • Endobronchial Valve Systems — Alternative minimally invasive approaches to severe emphysema treatment
  • Lung Volume Reduction Surgery — Invasive alternative to Zephyr Valve therapy for emphysema management
  • Pulmonary Rehabilitation Programs — Conservative management approach for COPD/emphysema patients

Recent Developments

  • (December 2025) New CFO Derrick Sung and other executives granted significant equity awards (1,625,000 shares total) under 2025 Inducement Plan
  • (September 2025) Management participation in Wells Fargo Healthcare Conference and Lake Street Best Ideas Growth Conference
  • (Q2 2025) Total revenue of $23.9M with 15% YoY growth; international revenue grew 32% to $9.1M

Open the full interactive Pulmonx Corporation report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →